EXACT Therapeutics AS ((DE:56F)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: EXACT Therapeutics AS is conducting a Phase 2 study titled A Phase 2 Study to Investigate the Efficacy and Safety of Acoustic Cluster Therapy With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer. The study aims to evaluate the effectiveness and safety of combining Acoustic Cluster Therapy (ACT) with chemotherapy for treating locally advanced pancreatic cancer, a significant step in improving outcomes for this challenging condition.
Intervention/Treatment: The study tests a combination of Acoustic Cluster Therapy, involving the drug PS101 and ultrasound, with modified FOLFIRINOX chemotherapy. This intervention is designed to enhance the treatment’s impact on pancreatic tumors.
Study Design: This interventional study uses a single-group model without masking, focusing on treatment as its primary purpose. Patients receive ACT and chemotherapy in cycles, with regular assessments to monitor treatment efficacy and safety.
Study Timeline: The study began on June 19, 2025, with recruitment currently underway. The primary completion and estimated study completion dates are yet to be announced, with the last update submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and potential market impact.
Market Implications: This study update could positively influence EXACT Therapeutics AS’s stock performance by showcasing innovation in cancer treatment. Investors may view this as a promising development in the competitive oncology market, potentially boosting confidence and interest in the company’s future prospects.
The study is ongoing, with further details available on the ClinicalTrials portal.